Carregant...
Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios
Immune checkpoint blockade has shown anti-tumour activity and improved survival in advanced non-small cell lung cancer (NSCLC). A number of anti-PD-1/PD-L1 and CTLA-4 monoclonal antibody agents have been evaluated in metastatic non-small cell lung cancer. Nivolumab, pembrolizumab and atezolizumab ar...
Guardat en:
| Publicat a: | J Thorac Dis |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AME Publishing Company
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5994491/ https://ncbi.nlm.nih.gov/pubmed/29951301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.01.80 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|